Onkologie. 2013:7(6):287-292

Neoadjuvant treatment of rectal adenocarcinoma

Igor Richter1, Josef Dvořák2, Jiří Bartoš1
1 Onkologické oddělení, Krajská nemocnice Liberec, a.s.
2 Klinika onkologie a radioterapie, Fakultní nemocnice Hradec Králové

Treatment of the rectal adenocarcinoma is multidisciplinary. Radiotherapy is the important component of the treatment. Neoadjuvant

chemoradiotherapy is indicated in tumours T3–4 or in the case of positive lymph nodes. 5-fluorouracil (5-FU) and capecitabine are the

most used cytostatik in combination with radiotherapy. The aim the neoadjuavnt treatment is attainment circumeferential radial margin

(CRM) after total mesorectal excision (TME).

Keywords: rectal adenocarcinoma, radiotherapy, chemotherapy, neoadjuvant treatment

Published: December 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Richter I, Dvořák J, Bartoš J. Neoadjuvant treatment of rectal adenocarcinoma. Onkologie. 2013;7(6):287-292.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Colorectal Collaborative Group: Adjuvant radiotherapy for rectal cancer: a systemic overview of 8507 patients from 22 randomised trials. Lancet 2001; 358:1291-1304. Go to original source... Go to PubMed...
    2. Bujko K, Kepka L, Michalski W, et al. Does rectal cancer shrinkage by preoperative radio (chemoútherapy increase the likelihood of anterior resection? A systemic review of randomised trilas. Radiother Oncol 2006; 80: 4-12. Go to original source... Go to PubMed...
    3. Wong RK, Tandan V, De Silva S, et al. Pre-operative radiotherapy and curative Sumery for the management of lacalized rectal carcinoma. Cochrane Database Syst Rev 2007; CD002102. Go to original source...
    4. Sauer R, Becker H, Hohenberger W, et al. Preoperative vesrus postoperative chemoradiotherapy for rectal cancer. N Eng J Med 2004; 351: 1731-1740. Go to original source... Go to PubMed...
    5. Wagman R, Misnky BD, Cohen AM, et al. Sphnicter preservativ in rectal cancer with preoperative radiation therapy and coloanal anastomosis: lon term follow-up. Int J Radiat Oncol Biol Phys 1998; 42: 51-57. Go to original source... Go to PubMed...
    6. Sauer R, Liersch T, Merkel S, et al. Preoperative vesrus postoperative chemoradiotherapy for rectal cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-up of 11 Yaers. J Clin Oncol 2012; 30: 1926-1933. Go to original source... Go to PubMed...
    7. Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary resuults EORTC 22921. J clon Oncol 2005; 23: 5620-5627. Go to original source... Go to PubMed...
    8. Collette L, Bosset JF, den Dulk M, et al.Patients with curative resection of cT3-4 recatl cancer after preoperative radiotherapy or chemoradiotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the EORTC. J clin Oncol 2007; 25: 4379-4386. Go to original source... Go to PubMed...
    9. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorine in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24-4620-4625. Go to original source... Go to PubMed...
    10. Ceelen WP, Van Nieuwenhove Y, Fierens K, et al. Preoperative chemoradiathion versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2009: CD006041. Go to original source...
    11. Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase3 trial. Lancet Oncol 2012; 13:579-588. Go to original source... Go to PubMed...
    12. Roh MS, Yothers GA, O´Connell MJ, et al. The impal of capecitabine and oxaliplatine in the preoperative multimodality treatment in patiens with carcinoma of the rektum: NSABP R-04 (abstrakt). J Clin Oncol 2011; 29 (suppl): 3503. Go to original source...
    13. Aschele C, Cionini L, Lonardi S, et al. Primay tumor response to preoperative chemoradiotion with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phae III trial. J Clin Oncol 2011; 29: 2773-2780. Go to original source... Go to PubMed...
    14. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regiment for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405 - Prodige 2. J Clin Oncol 2010; 28: 1638-1644. Go to original source... Go to PubMed...
    15. Rodel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postpostoperative chemiotherapy with fluorouracil and oxaliplatine versus fluorouracil alone in locally advanced rectal cancer: initial results of German CAO/ ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012. Go to original source... Go to PubMed...
    16. Folkesson J, Birgisson H, Pahlman L, et al. Swedisch Rectal cancer Trial: long lasting benefits from radiotherapy on survival and local recurence rate. J Clin Oncol 2005; 23: 5644-5650. Go to original source... Go to PubMed...
    17. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preopperative radiotherapy combined with total mesorectal exciton for resectable rectal cancer. N Engl J Med 2001; 345: 638-646. Go to original source... Go to PubMed...
    18. Marijnen CA, Nagtegaal ID, Kapiteijn E, et al. Radiotjerapy does not compensate for positive resection margine in rectal cancer petients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003; 55: 1311-1320. Go to original source... Go to PubMed...
    19. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93: 1215-1223. Go to original source... Go to PubMed...
    20. Guillem JG, Diaz-Gonzalez JA, Minsky BD, et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008; 26: 368-373. Go to original source... Go to PubMed...
    21. Saunders MP, Alderson H, Chittalia A, et al. Preoperative radiotherapy for operable rectal cancer - is a Loir dose to a reduced volume actetable? Clin Oncol 2006; 18:594-599. Go to original source... Go to PubMed...
    22. Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and Sumery on downstaging and on the rate of sphincter-sparing Sumery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999; 17: 2396. Go to original source... Go to PubMed...
    23. Mohiuddin M, Winter K, Mitschell E, et al. Randomized phase II study of neoadjuvant combinated modality chemoradiation for distal rectal cancer: RTOG trial 0012. J Clin Oncol 2006; 24: 650-655. Go to original source... Go to PubMed...
    24. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatine followed by synchronous chemoradiation and total mesorectal exciton in magnetic resonance paging defined poor risk rectal cancer. J Clin Oncol 2006; 24: 668-674. Go to original source... Go to PubMed...
    25. Fernandez-Martos C, Aparicio J, Salud A, et al. Multicenter randomized phase II study of chemoradiation (CRT) followed by Sumery (S) and chemotherapy (CT) versus induction CT followed by CRT and S in high-risk rectal cancer: GCR3 final efficacy and safety results. ASCO Meeting Abstracts 2009; 27: 4103. Go to original source...
    26. Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal exciton in patiens with high-ris rectal cancer (EXPERT-C). J Clin Oncol 2012; 30:1620-1627. Go to original source... Go to PubMed...
    27. Chiorean EG, Sanghani S, Schiel MA, et al. Phase II and gene expression analysis trila of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based. chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. Cancer Chemother Pharmacol 2012; 70:25-32. Go to original source... Go to PubMed...
    28. Kim Sy, Hong YS, Kim Dy, et al. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patiens with locally advanced resectable rectal cancer: a multicenter Phase II study. In J Radiat Oncol Biol Phys 2011; 81:677-683. Go to original source... Go to PubMed...
    29. Speigel DR, Bendell JC, McCleod M, et al. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patiens with stage II/III rectal cancer. Clin Colorectal Cancer 2012; 11:45-52. Go to original source... Go to PubMed...
    30. Habr-Gama A, Perez RO, Proscurshim I, et al. Interval between Sumery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed Sumery have an impal on outcome? Int J Radioat Oncol Biol Phys 2008; 71:1181-1188. Go to original source... Go to PubMed...
    31. Moore HG, Gittleman AE, Minsky BD, et al. Rate of pathologic komplete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Coln Rectum 2004; 47: 279-286. Go to original source... Go to PubMed...
    32. Patel UB, Taylor F, Blomqvist L, et al. Magnetic resonance paging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011; 29: 3753-3760. Go to original source... Go to PubMed...
    33. Rodel C, Martus P, Papadoupolos T, et al. Prosnostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005; 23:8688-8696. Go to original source... Go to PubMed...
    34. Janjan NA, Crane C, Feig BW, et al. Improvede overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol. 2001; 24:107-112. Go to original source... Go to PubMed...
    35. Janjan Na, Abbruzzese J, Pazdur R et al. Prognostic implications of response to preoperative infusionla chemoradiation in locally advanced rectal cancer. Radiother Oncol. 1999; 51: 153-160. Go to original source... Go to PubMed...
    36. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of indivudual patient data. Lancet Oncol. 2010; 11: 835-844. Go to original source... Go to PubMed...
    37. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatine compared with fluorouracil/folinic acid plus oxaliplatine as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008; 26: 2006-2012. Go to original source... Go to PubMed...
    38. Fuschs CS, Marshall J, Mitchell E, et al. Randomized controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from BICC-C Study. J Clin Oncol. 2007; 25: 4779-4789. Go to original source... Go to PubMed...
    39. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatine compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29: 1465-1471. Go to original source... Go to PubMed...
    40. Shimma N, Umeda I, Arasaki M et al. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Biorg Med Chem 200; 8:1697-16706. Go to original source... Go to PubMed...
    41. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-297. Go to original source... Go to PubMed...
    42. Lamond JP, Wang M, Kinsella TJ, et al. Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors. Int J Radiat Oncol biol Phys 1996; 36: 369-376. Go to original source... Go to PubMed...
    43. Tamura K, Takad M, Kawase I, et al. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res 1997; 88:218-223. Go to original source... Go to PubMed...
    44. Mohiuddin M, Winter K, Mitchell E et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncol Group Trial 0012. J Clin Oncol 2006; 20:519-524. Go to original source... Go to PubMed...
    45. Rodel C, Hofheinz R, Liersch T, et al. Rectal cancer: state of art in 2012. Curr Opin Oncol 2012; 24: 441-447.
    46. Dvořák J, Sitorová V, Ryška A et al. The prognostic signifikance of ganges of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patiens with rectal adenocarcinoma. Strahlenter Onkol 2012; 10: 145-147. Go to original source... Go to PubMed...
    47. Kocáková I, Soumarová R. chemoradioterapie karcinomu konečníku s 62-72. In: Šlampa P, Soumarová R, Kocáková I. et al.: Konkomitantní chemoradioterapie solidních nádorů. Nakladatelství Galén 2005, 167 s.
    48. Doleželová-Horová H, Ondrová B, Šlampa P, et al.: Karcinom konečníku s. 153-162. In: Šlampa P, Petera J et al.: Radiační onkologie. Nakladatelství Galén Praha; Nakladatelství Karolinum Praha; 2007; 1. Vydání, 457 s.
    49. Šlampa P, Lovas P. současný pohled na chemoradioterapii karcinomu rekta. Kolorektální karcinom 2009, Farmakoterapie 2009; 5, speciální příloha: 44-49.
    50. Richter I, Dvořák J. Farmakoterapie metastatického kolorektálního karcinomu - současné možnosti. Remedia 2011; 21:650-656.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.